Kaplan-Meier survival analysis for non-metastatic (tumour stage 0,1,2,3) patients showed that those who mounted a CD8+ T cell response to Her-2 and also possessed low levels (<median) of MDSC-1 had better survival (log-rank test: P = 0.01) than patients with no CD8 T cell response to Her-2 and high levels of MDSC-1 (Figure 5A). This evidence concerns the gene CD8A and neoplasm.